Volume 87, Issue 1, Pages (January 2015)

Slides:

Advertisements

Similar presentations

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Advertisements

Volume 58, Issue 1, Pages (July 2000)

Intensive hemodialysis—keeping the faith

Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward Adeera Levin, Paul E. Stevens Kidney International

Propofol-related green urine

Anemia management in chronic kidney disease

Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

C-reactive protein and dialysis access

Intensive hemodialysis—keeping the faith

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

C-reactive protein and dialysis access

Volume 77, Issue 1, Pages 6-8 (January 2010)

Need for better diabetes treatment for improved renal outcome

日本人小児のためのeGFR推算式 (19歳未満に適応）

Volume 85, Issue 5, Pages (May 2014)

Volume 87, Issue 1, Pages (January 2015)

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Volume 77, Issue 1, Pages 5-6 (January 2010)

Volume 92, Issue 1, Pages (July 2017)

Methotrexate in the urine

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion Lynda A. Frassetto, Eileen Nash,

Nephrology Crosswords: Hemodialysis

Volume 79, Issue 9, Pages (May 2011)

Volume 87, Issue 2, Pages (February 2015)

Volume 75, Issue 8, Pages (April 2009)

U-shaped effect of eGFR and mortality

Volume 87, Issue 1, Pages (January 2015)

Nephrology Crossword: History of nephrology

Volume 73, Issue 10, Pages (May 2008)

Infected glomerulus Kidney International

Volume 82, Issue 1, Pages 3-4 (July 2012)

Volume 87, Issue 1, Pages (January 2015)

A physician's perseverance uncovers problems in a key nephrology study

Günter Weiss, Florian Kronenberg Kidney International

The third World Kidney Day: Looking back and thinking forward

Volume 82, Issue 10, Pages (November 2012)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 74, Issue 8, Pages (October 2008)

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Methods for guideline development

Volume 85, Issue 1, Pages 3-4 (January 2014)

Simvastatin in nephrotic syndrome

Volume 78, Issue 5, Pages (September 2010)

Nephrology Crossword: Glomerulonephritis

Unilateral renal cystic disease

Volume 71, Issue 4, Pages (February 2007)

A man with a hole in his penis

Volume 78, Issue 5, Pages (September 2010)

Volume 82, Issue 9, Pages (November 2012)

Volume 81, Issue 1, Pages 7-9 (January 2012)

The course of the remnant kidney model in mice

Volume 67, Issue 4, Pages (April 2005)

Volume 76, Issue 1, Pages 8-10 (July 2009)

Volume 59, Issue 5, Pages (May 2001)

The changing face of childhood nephrotic syndrome

Adiponectin: good, bad, or just plain ugly?

Dana V. Rizk, David G. Warnock Kidney International

Hisataka Kobayashi, Peter L. Choyke Kidney International

The international realities of live donor kidney transplantation

Antioxidant therapy in hemodialysis patients: a systematic review

Volume 85, Issue 6, Pages (June 2014)

Negative trials in nephrology: what can we learn?

Volume 75, Issue 8, Pages (April 2009)

Prediction in idiopathic membranous nephropathy

The Ebf1 knockout mouse and glomerular maturation

Presentation transcript:

Volume 87, Issue 1, Pages 225-232 (January 2015) A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment Norishige Yoshikawa, Koichi Nakanishi, Mayumi Sako, Mari S. Oba, Rintaro Mori, Erika Ota, Kenji Ishikura, Hiroshi Hataya, Masataka Honda, Shuichi Ito, Yuko Shima, Hiroshi Kaito, Kandai Nozu, Hidefumi Nakamura, Takashi Igarashi, Yasuo Ohashi, Kazumoto Iijima Kidney International Volume 87, Issue 1, Pages 225-232 (January 2015) DOI: 10.1038/ki.2014.260 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 Trial profile. Kidney International 2015 87, 225-232DOI: (10.1038/ki.2014.260) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 2 Kaplan–Meier estimates of time to frequently relapsing nephrotic syndrome (FRNS). HR, hazard ratio. Kidney International 2015 87, 225-232DOI: (10.1038/ki.2014.260) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Kaplan–Meier estimates of time to first relapse. HR, hazard ratio. Kidney International 2015 87, 225-232DOI: (10.1038/ki.2014.260) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 4 Initial treatment regimens. Upper doses are in mg/m2 per day. Maximum doses are in mg/day. D, daily; AD, alternate days. Kidney International 2015 87, 225-232DOI: (10.1038/ki.2014.260) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 5 Treatment regimens for relapse.aUntil urinary protein is negative on 3 consecutive days using a urine dipstick test. Upper doses are in mg/m2/day. A maximum dose of each is the same as initial treatments in Figure 4. AD, alternate days; D, daily. Kidney International 2015 87, 225-232DOI: (10.1038/ki.2014.260) Copyright © 2015 International Society of Nephrology Terms and Conditions